Shattuck Labs appoints Dr. Clay Siegall and Dr. Kate Sasser to board of directors

Shattuck Labs, Inc.

Appointments effective March 1, 2024; board now includes two new independent directors.
Dr. Siegall is CEO/Chairman of Immunome (IMNM) and former CEO/Chairman of Seagen (acquired by Pfizer).
Dr. Sasser is Chief Scientific Officer of Tempus AI and previously led translational research at Genmab and J&J.
Co. expects clinical updates for SL-172154 mid-2024 and plans late-stage/pivotal studies in multiple indications.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Clay Siegall

Class III director

STTK · Shattuck Labs, Inc.

Effective: 2024-03-01
Filed: March 4, 2024, 6:59 PM ET

On March 1, 2024, the Board of Directors (the “Board”) of Shattuck Labs, Inc. (the “Company”) expanded its size and appointed: (i) Dr. Kate Sasser as a Class II director to serve until the Company’s 2025 Annual Meeting of Stockholders and until her successor is duly elected and qualified and (ii) Dr. Clay Siegall as a Class III director to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified, effective immediately.

Appointed

Dr. Kate Sasser

Class II director

STTK · Shattuck Labs, Inc.

Effective: 2024-03-01
Filed: March 4, 2024, 6:59 PM ET

On March 1, 2024, the Board of Directors (the “Board”) of Shattuck Labs, Inc. (the “Company”) expanded its size and appointed: (i) Dr. Kate Sasser as a Class II director to serve until the Company’s 2025 Annual Meeting of Stockholders and until her successor is duly elected and qualified and (ii) Dr. Clay Siegall as a Class III director to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Clay Siegall was appointed as Class III director at Shattuck Labs, Inc..

Action: appointed
Role: Class III director

Exact text from the filing

On March 1, 2024, the Board of Directors (the “Board”) of Shattuck Labs, Inc. (the “Company”) expanded its size and appointed: (i) Dr. Kate Sasser as a Class II director to serve until the Company’s 2025 Annual Meeting of Stockholders and until her successor is duly elected and qualified and (ii) Dr. Clay Siegall as a Class III director to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Kate Sasser was appointed as Class II director at Shattuck Labs, Inc..

Action: appointed
Role: Class II director

Exact text from the filing

On March 1, 2024, the Board of Directors (the “Board”) of Shattuck Labs, Inc. (the “Company”) expanded its size and appointed: (i) Dr. Kate Sasser as a Class II director to serve until the Company’s 2025 Annual Meeting of Stockholders and until her successor is duly elected and qualified and (ii) Dr. Clay Siegall as a Class III director to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified, effective immediately.

View on SEC.gov

Shattuck Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-056839

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.